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Polylactide (PLA) microspheres were prepared using the solid-in-oil (S/O) spray-drying method to achieve the sustained re-
lease of a hydrophilic drug for the treatment of tuberculosis, via intratracheal instillation. Isoniazid (IN), a 
low-molecular-weight hydrophilic drug, was used as a model drug. The effects of various sizes of micronized IN powder, dif-
ferent drug/polymer ratios, spray-drying process parameters, and drug-release characteristics were studied to optimize the 
manufacturing parameters. A high entrapment efficiency (87.3%) was obtained using this method; furthermore, the micro-
spheres were spherical and smooth. They were individually and homogenously distributed, with a mean diameter of 5.6 μm; 
furthermore, they showed a satisfactory extended sustained-release phase. After administration of the microspheres to rats, 
pulmonary drug concentrations were maintained at a relatively stable level for up to 4 weeks. 
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Tuberculosis (TB) is a chronic infectious disease caused by 
the tubercle bacillus. Despite the development of treatment 
programs and various anti-TB drugs, TB remains a globally 
serious infectious disease (Nahid and Menzies, 2012). Since 
most of the TB manifestations are observed mainly in the 
respiratory system, pulmonary drug delivery has received 
increasing attention (Kulik, 1980; Misra et al., 2011; Pan-
dey and Khuller, 2005). The pulmonary delivery of drugs 
via intratracheal instillation has been increasingly used for 
the clinical treatment of TB (Fu et al., 2008; Pourshahab et 
al., 2011; Zahoor et al., 2005). Using the pulmonary topical 
delivery route, anti-TB drugs are likely to gather in the 
lungs more rapidly and at higher concentrations without 
first-pass metabolism, which could enhance the bioavaila-
bility of drugs at their site of action (Furak et al., 2001). In 
addition, this route reduces systemic adverse effects (Sa-
dovnikov, 1993). However, one of the main problems asso-
ciated with intratracheal instillation is that it is difficult to 
maintain a therapeutic drug concentration for the required 
duration. Frequent dosing is generally associated with worse 
compliance to the TB treatment; therefore, developing a 
sustained-release drug delivery system is particularly im-
portant in order to improve the therapeutic efficacy. A 
standard therapy regime involves chemotherapy using ri-
fampicin (RIP) and isoniazid (IN), supplemented with 
streptomycin or ethambutol for six to nine months (Somner, 
1975).  
In previous studies, we designed two kinds of drug-   
delivery systems, poly(lactic-co-glycolic acid) (PLGA) mi-
crospheres in a sodium alginate gel for rifampicin (RFP) 
delivery (Hu et al., 2012) and ethyl cellulose-chitosan com-
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plex microspheres for rifabutin (RBT) delivery (Feng et al., 
2013). These delivery systems prolonged drug retention in 
the lungs, which lead to the maintenance of the therapeutic 
drug concentration for at least 24 d. Compared to the lipo-
philic drugs (RFB and RIP), it is more difficult to maintain 
a sustained delivery of the low-molecular-weight hydro-
philic drug, IN, in the lungs. 
Polylactide (PLA) is widely used to prepare sustained 
delivery systems; the most common manufacturing method 
is the double emulsification (W/O/W) procedure (Gallarate 
et al., 2009; Liu et al., 2006; Mun et al., 2010; Yin et al., 
2006). Currently, microspheres loaded with hydrophilic 
drugs, especially those with, low molecular weights, still 
suffer from two major problems; low drug loading efficien-
cy and burst release behavior (Freiberg et al, 2004; Huang 
and Brazel, 2001; Park et al, 1992a, b; Wang et al, 1991). 
The main reasons for the problems were the migration of 
the drug, porous structure of microspheres, and heteroge-
neous distribution of the drug in the polymer matrix. Based 
on these factors, extensive research has been carried out.  
In this study, PLA microspheres loaded with IN 
(PLA-IN-MS) were prepared using the solid-in-oil (S/O) 
spray-drying method. Unlike in the W/O/W emulsion 
method, micronized IN powder was used instead of a drug 
solution. Therefore, there was no outer water phase, which 
helps to eliminate the osmotic pressures and decreases drug 
migration; therefore, it may improve the drug loading effi-
ciency. In order to uniformly disperse the drug in the or-
ganic solvent, IN powder was micronized via ball milling. 
The in vitro/in vivo release behaviors were studied to clarify 
the sustained-release properties of the microspheres. 
RESULTS AND DISCUSSION 
Currently, inhalation and intratracheal instillation are two 
techniques used for the pulmonary administration of drugs 
(Coowanitwong et al., 2008; Yoshida et al., 2006). Howev-
er, pharyngeal deposition associated with the inhalation 
route may lead to difficulties in measuring the dose inside 
the lungs, and side effects associated with the systemic cir-
culation (Tomoda et al., 2008; Tsapis et al., 2003). In con-
trast, an intratracheal instillation is a simple, quantifiable 
way to achieve pulmonary drug delivery, and has been in-
creasingly applied in the clinical treatment of pulmonary 
tuberculosis. 
Microspheres have been widely reported as one of the 
better formulations for pulmonary administration. However, 
microspheres prepared using the W/O/W method (Gallarate 
et al., 2009; Liu et al., 2006; Mun et al., 2010; Yin et al., 
2006) have two major problems: a low drug loading effi-
ciency and burst release behavior (Freiberg et al., 2004; 
Huang and Brazel, 2001; Park et al., 1992a, b; Wang et al., 
1991). 
In order to restrict drug diffusion, the S/O/W emulsion 
method was used in this study. This emulsion method has 
been used in protein and peptide delivery systems. Owing to 
the low thermal energy state of the solid state, drug particles 
have a less tendency to migrate from the oil phase to aque-
ous phase and, therefore, a higher drug loading efficiency 
was expected.  
Preparation of micronized IN powder 
In our previous study, we found that the size of the IN 
powder particles affected the loading capacity (LC) and 
entrapment efficiency (EE); smaller powder particles re-
sulted in higher LC and EE values. 
Factors including the rotation speed, milling time, dif-
ferent IN/ball weight ratios, and the volume of dichloro-
methane (DCM) were studied for their possible influences 
on the particle size of the micronized IN powder, in order to 
optimize the preparation process, as reported in Table 1. A 
smaller particle size was observed at a milling speed of 650 
rpm for 2 h, with 3 mL of DCM and an IN/ball weight ratio 
of 0.5/30. It was shown that the particle size decreased 
when the grinding time was prolonged from 1 to 2 h; how-
ever, the particle size increased when the grinding time was 
prolonged further, which resulted from inverse crushing. 
Inverse crushing is a phenomenon where particles agglom-
erate together, eliciting an apparent size increase when the 
milling time exceeds a certain period of time. Therefore, the 
appropriate extension of the milling time can improve the 
grinding efficiency; however, further extension will not 
only decrease the milling efficiency, but also contribute to 
the inverse crushing phenomenon. When the other parame-
ters were kept constant, the particle size reduced with a de-
creasing IN/ball ratio. With the ratio of ball increasing, the 
probability of the ball affecting the IN particles increased; 
furthermore, the energy transferred to the IN particles in-
creased, resulting in smaller-sized particles. Adding DCM 
significantly decreased the particle size of the IN powder. 
We found that the IN powder mostly sank to the bottom of 
the tank without the addition of DCM; moreover, the balls 
were on top of the powder, which meant that the impaction 
of the balls on the powder was insufficient. After the addi-
tion of DCM, the IN powder adhered to the balls during the 
milling process and sufficient impaction was achieved. An-
other reason for the decreased IN powder particle size is 
that the crushing process can generate new surfaces upon 
which the surrounding medium can adsorb. This would re-
duce the particle strength and increase their deformation, 
resulting in the further breakdown of the particles. Con-
versely, more work is required to produce new surfaces in a 
vacuum than in liquid medium. The optimized processing 
parameters for the IN powder were as follows: 0.5 g of IN 
and a 2 h milling time, 30 g balls, and 3 mL of DCM.  
Preparation of microspheres 
Previous research (Nahid and Menzies, 2012) indicated that 
when the microspheres were prepared using the W/O/W 
method, hydrophilic drugs exhibited a significant tendency 
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Table 1  Effects of rotation speed, milling time, amount of isoniazid (IN) and balls, and the volume of DCM on the particle size of micronized IN powder 
Rotation speed (rpm) Milling time (h) IN (g) Balls (g) DCM (mL) Particle size (μm) 
450 2 1 30 3 4.560±0.583 
550 2 1 30 3 1.560±0.352 
650 2 1 30 3 0.683±0.267 
650 3 1 30 3 1.206±0.372 
650 1 1 30 3 1.887±0.342 
650 2 0.5 30 3 0.161±0.102 
650 2 1 20 3 0.445±0.136 
650 2 1 10 3 2.262±0.353 
650 2 1 30 2 0.534±0.336 
650 2 1 30 − 4.762±0.103 
Table 2  Effect of the isoniazid particle size and drug/polylactide (PLA) mass ratio on the entrapment efficiency (EE) and loading capacity (LC) of 
PLA-IN-microspheres (mean±SD, n=3) 
No. IN/PLA Size of IN (nm) LC % EE % 
1 40/800 1560±0.352 3.86±0.26 76.81±2.06 
2 40/800 683±0.267 4.61±0.26 80.46±1.85 
3 40/800 161±0.106 5.43±0.26 89.32±1.21 
4 60/800 161±0.106 7.23±1.08 84.30±2.38 
5 80/800 161±0.106 9.16±0.96 80.17±1.59 
 
to migrate from the inner water phase to the outer water 
phase during the preparation process, resulting in a low drug 
loading efficiency. Moreover, the migration of water that 
carries a drug during drying and storage may lead to a het-
erogeneous drug distribution in the polymer matrix, which 
increases the probability of a burst release.  
Dutt and Khuller controlled microsphere pores by ad-
justing the concentrations of PLGA and poly(vinyl alcohol) 
(PVA) (Dutt and Khuller, 2011); they found that the sus-
tained release of IN was prolonged with the incorporation of 
sphere porosity. Although the hardened PLGA micro-
spheres met the sustained-release standard, the percentage 
entrapment of IN was only 10%–11%. Ito et al. prepared 
IN-PLGA microspheres by freezing the inner water phase of 
the primary W/(O1+O2) emulsion at −10°C, followed by the 
evaporation of the solvent from the secondary 
W/(O1+O2)/O3 emulsion (Ito et al., 2011). This procedure 
eliminated the rapid diffusion of the drug to the outer phase. 
However, although the drug loading efficiency was im-
proved to approximately 20%, the preparation process is 
complicated and difficult to control. Thus, in order to im-
prove the loading efficiency and reduce the burst release, it 
is necessary to restrict the migration of the drug. 
In this study, PLA microspheres loaded with IN 
(PLA-IN-MS) were prepared using the solid-in-oil (S/O) 
spray-drying method and an EE above 80% was achieved 
(Table 2). Unlike in the W/O/W emulsion method, mi-
cronized IN powder was used instead of a drug solution and 
there was no outer water phase, which could be helpful for 
eliminating the osmotic pressures and decreasing drug mi-
gration. 
The traditional spray-dryer that is reported in most of the 
literature uses pressure nozzles and rotary atomizers or a 
two-fluid nozzle for forming spray droplets. The droplets in 
the gas flow through an L drying chamber, and are collected 
in a cyclone collector. During the process, collisions be-
tween droplets and the tube wall easily occur due to the 
strong flow of gas. It is difficult to collect microspheres 
from the cyclone collector, and the particles are irregular in 
shape. A Nano Spray Dryer B-90 (BÜCHI Labortechnik 
AG, Switzerland) was used in this study, which utilizes a 
vibrating mesh technology for the generation of fine drop-
lets. The spray-drying process is delicate and the size of 
droplets is mainly controlled by the size of the hole. Fur-
thermore, the spray-dryer has a vertical configuration, facil-
itating direct and straight-down collection of the particles 
into the collector, which helps to minimize the collision 
between the microspheres and the side walls, and results in 
a mostly spherical particle shape.  
The results showed that a smaller drug particle size con-
tributed to a higher EE and drug loading. Therefore, IN 
powder with a particle size of approximately 0.16 μm was 
used in the next studies. 
As shown in Table 2, the LC rose as the proportion of IN 
to PLA increased; however, the EE dropped. We found that 
with an increase in the IN particle ratio, the residue of drug 
particles left on the bottom of the bottle increased. It was 
thought that the ability of the DCM solution containing 
PLA to support IN powder was limited. In addition, with the 
increase of the IN particle ratio, aggregation occurred be-
tween the powder particles due to electrostatic adsorption. 
These aggregates were then deposited on the bottom of the 
bottle, causing the EE to reduce. 
The optimized parameters for the PLA-IN-MS were as 
follows: an IN/PLA ratio of 60/80 and an IN powder parti-
cle size of approximately 161 nm. 
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Morphology and particle size distribution of micro-
spheres 
Most polymeric microspheres prepared via the spray-drying 
technique have been reported to have an irregular spherical 
morphology with pores on the surface (Bodmeier and Chen, 
1988; Gavini et al., 2004). However, microspheres with 
spherical and smooth surfaces were obtained in our study, 
as shown in Figure 1. This morphology was mainly at-
tributed to the distinctive spray and collection mechanism of 
the Nano Spray Dryer B-90 that owns three patented tech-
nologies (a Piezo electric spray head, a patented heating 
system, and an electrostatic particle collector), which ena-
bled the production of small particles and reduced the R&D 
cost owing to small sample volumes and higher yields.  
Furthermore, an enlarged view of one microsphere (Fig-
ure 1B) revealed that there were no obvious pores and 
cracks on the surface of the microsphere. The mean particle 
size of the microspheres was approximately 5.6 μm. 
Differential scanning calorimetry (DSC) measurements 
DSC curves of microspheres loaded with IN were drawn in 
comparison with PLA microspheres (Blank-MS), IN, and 
their physical mixture (PLA-IN-MIX; Figure 2). 
Ball milling is a high-speed operation and the drug crys-
tal form may change during the process; furthermore, deg-
radation and oxidation may occur owing to the heat produc-
tion as a result of high-speed grinding (Cai, 2004). For these 
reasons, we investigated the effect of the grinding process 
on the stability of the drug. The DSC endotherm of the IN 
sample shows a sharp melting endotherm at 175°C, and no 
significant differences were observed between micronized 
and non-micronized IN (Figure 2). These results indicate 
that crystal transformation did not occur during the mi-
cronization process; therefore, it can be used as a manufac-
turing step to reduce the particle size of IN, without chang-
ing its physical form. 
The blank microspheres have one endothermic peak 
(55°C), the physical mixture of the drug and blank micro-
spheres has two endothermal peaks (55°C and 175°C) cor-
responding to PLA blank microspheres and the drug, re-
spectively. However, the typical endothermic peaks of IN  
were not observed in the curve of the PLA-IN-MS, which 
illustrates the formation of microspheres and high EE of IN. 
In vitro drug release 
The in vitro release of IN from the loaded microspheres was 
studied for 512 h at pH 7.4 in phosphate-buffered saline 
(PBS). In this study, we compared the release rate of IN 
from microspheres (PLA-IN-MS) and the physical mixture 
(PLA-IN-MIX; Figure 3A). 
It was demonstrated that the in vitro release rate of IN 
from microspheres was significantly slower than that from 
the physical mixture. As shown in Figure 3A, the cumula-
tive release percentages of IN from the PLA-IN-MS and 
PLA-IN-MIX were compared, with 8.97% and 76.12% re-
leased in 0.5 h, 16.1% and 95.04% in 2 h, and 19.41% and 
98.01% in 4 h, respectively. Almost more than 90% of the 
IN was released from the physical mixture within 4 h, while 
there was a sustained release from the PLA-IN-MS, with 
only 9% of the drug released within the first 0.5 h, and a 
significantly reduced burst release.  
The microsphere suspension was vortex-mixed before 
administration, so the effect of this vortex-mixing was also 
studied. Compared to PLA-IN-MS, a faster release profile 
of IN was observed from the PLA-IN-MS after vor-
tex-mixing, with 32% of the drug released within the first 
0.5 h. It is reasonable to infer that the strong shear stress of 
the vortex-mixing carried surface-adhered drug from the 
microspheres to the medium and, therefore, enhanced drug 
dissolution. Furthermore, the shear stress also separated the 
microspheres, with a tremendously increased specific con-
tact area between the microspheres and dissolution medium, 
which resulted in the higher drug dissolution rate. 
As shown in Figure 3B, the percentage of IN released 
was 34.63% after 24 h, followed by a gradual and sustained 
release up to 70.12% after 552 h. The drug release behavior 
showed a biphasic pattern indicated by its initial quick re-
lease, followed by a very slow release. This initial quick 
release could be attributed to the vortex-mixing process of 
the microsphere suspension, which may facilitate drug dif-
fusion from the microsphere surface layer to the medium. 
After this initial period, the release may have occurred due 
to the diffusion of the drug from the PLA matrix of the mi-
crospheres into the dissolution medium.  
 
 
Figure 1  Scanning electron microscopy images of polylactide-isoniazid microspheres. 
728 Zhang, L., et al.   Sci China Life Sci   July (2016) Vol.59 No.7 
 
Figure 2  Differential scanning calorimetry study. A, Blank polylactide 
(PLA) microspheres (MS); B, PLA-IN-MIX; C, PLA-IN-MS; D, mi-
cronized IN; E, IN. 
 
Figure 3  In vitro release study (n=6). A, In vitro drug release of isoniazid 
(IN)-loaded microspheres (MS) after vortex-mixing, IN-loaded MS without 
vortex-mixing and a polylactide (PLA)-IN-physical mixture (MIX); B, In 
vitro drug release of IN-loaded MS after vortex-mixing for 512 h. 
In vivo drug release 
The bronchoalveolar lavage (BAL) method was used to 
extract free IN from the lungs of treated rats, as described in 
the MATERIALS AND METHODS. After the administra-
tion of the PLA-IN-MS, the lungs were separated and in-
jected with PBS. The lavage fluid was collected and the free 
drug was extracted using DCM. 
As shown in Figure 4A, the concentration of IN immedi-
ately reached 2,659.7 ng mL−1 5 min after administration of 
the physical mixture of PLA and IN (PLA-IN-MIX), which 
was almost ten times more than the maximum drug concen-
tration of the test group. The drug concentration then 
sharply decreased to 23.9 ng mL−1 after 30 min. After 2 h, 
no more drug was detected in the physical mixture samples, 
whereas IN was still releasing slowly from the PLA micro-
spheres. 
A Cmax of 244.8 ng mL−1 was immediately achieved 0.5 h 
after administration of the PLA-IN-MS (Figure 4A). The 
concentration decreased to 80.0 ng mL−1 after 24 h, fol-
lowed by a plateau level of approximately 60 ng mL−1 that 
lasted over 14 d (Figure 4B), which then gradually de-
creased to 32.8 ng mL−1 after 28 d. Both of these concen-
trations were higher than the minimal inhibitory concentra-
tion (MIC) of IN, which is 25 ng mL−1. 
The in vitro release study revealed that vortex-mixing 
affected the drug release; therefore, the intense vor-
tex-mixing used for the preparation of the PLA-IN-MS 
suspension is probably responsible for the initial release 
peak demonstrated in the in vivo experiment. Although an 
initial burst release was observed, the MS exhibited a sus-
tained release for up to 4 weeks, which is promising for 
reducing the frequency of drug administration and improv-
ing the therapeutic efficacy of the intratracheal treatment of 
TB.  
MATERIALS AND METHODS 
Materials 
IN was purchased from Sigma-Aldrich, USA. PLA with a 
viscosity of 0.49 dL g−1 (in CHCl3 at 25°C) was obtained  
 
 
Figure 4  Pulmonary isoniazid (IN) concentration vs. time profiles of 
IN-polylactide (PLA) microspheres (MS) following intratracheal instilla-
tion to rats (mean±SD, n=6). 
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from the Shandong Institute of Medical Instruments, China. 
IN (99.5% purity) standard and internal standard (I.S.) gat-
ifloxacin (98.0% purity) were purchased from the National 
Institute for Food and Drug Control, China. DCM was pur-
chased from the Beijing Chemical Plant, China. Methanol 
was of HPLC grade (Dikma, USA). Formic acid (AR grade) 
was purchased from Yongda Chemical Reagent Factory of 
Tianjin, China. 
Animals 
Male Sprague-Dawley (SD) rats weighing from 250 to 300 
g were obtained from Vital River Laboratories, China. Be-
fore the study, the rats were allowed to acclimatize to the 
environment for 7 d. All studies involving animals were 
performed in accordance with the Guide for the Care and 
Use of Laboratory Animals. 
Preparation of micronized IN powder 
Micronized IN powder was prepared using the ball-milling 
method with a planetary ball miller (RETSCH PM100, 
Germany). Alumina balls (2.7 mm diameter), IN, and DCM 
were loaded into a 25 mL stainless steel jar, and then 
ground at low (450 rpm), medium (550 rpm), and high (650 
rpm) speeds. The effect of different amounts of IN, balls, 
and DCM were also studied. The micronized IN powder 
was collected after the DCM was evaporated. The particle 
size of the micronized IN powder was analyzed using a 
Malvern Zetasizer Nano ZS90 (Malvern Instruments, UK). 
Preparation of microspheres 
Drug-loaded microspheres (PLA-IN-MS) were prepared 
using the spray-drying method. Micronized IN powder was 
dispersed in DCM under sonication for 5 min; subsequently, 
PLA was added and sonicated until the PLA dissolved. The 
suspension was then spray-dried using a Nano Spray Dryer 
B-90 (BÜCHI Labortechnik AG, Switzerland). The operat-
ing conditions were kept constant as follows: Tm=100°C, 
feed rate=15 mL h−1, and drying gas flow rate=100 L min−1. 
Under these conditions, the microspheres were sufficiently 
dried and less microspheres remained on the wall of the 
structure. The spray mesh used in this study was a mem-
brane with 7.0 μm-sized holes. 
Blank-MS were prepared using the same method as de-
scribed for the PLA-IN-MS, without the addition of IN. 
A physical mixture of IN and Blank-MS, PLA-IN-MIX, 
was prepared by mixing IN micronized powder and 
Blank-MS at the same ratio of IN to PLA as that used for 
the PLA-IN-MS. 
Particle size analysis 
Most of the sizes of the particles that made up the mi-
cronized IN powder were at the nanometer level, thus, a 
Malvern Zetasizer Nano ZS90 (Malvern Instruments, UK) 
was used, which has a measuring range from 0.3 nm to 10 
μm. The specific operation of the instrument was as fol-
lows: 10 mg of microspheres and an equal amount of sodi-
um lauryl sulfate were mixed, and then this mixture was 
ultrasonically dispersed in 4 mL of distilled water. Finally, 
the suspension was put into the sampling beaker of the in-
strument and analyzed. IN powder was ultrasonically dis-
persed in DCM, and then this suspension was analyzed. 
Scanning electron microscopy (SEM) 
The microscopic shape and surface morphology of the mi-
crospheres were observed using SEM (JSM-6510, Japan). 
Microspheres were dispersed on aluminum stubs and then 
sputter-coated with platinum particles for 120 s. The sam-
ples were then observed at an accelerating voltage of 15 kV, 
with the observation magnitude set at 10 mm. 
DSC 
Microspheres loaded with IN were characterized using DSC 
(Q200, TA Instruments, USA). Five samples were prepared 
in this study: IN, micronized IN, Blank-MS; PLA-IN-MS, 
and PLA-IN-MIX. Five milligrams of each sample was 
heated up from 0°C to 250°C at a speed of 10°C min−1. An 
empty sample pan was used as a reference. 
High-performance liquid chromatography (HPLC) 
A Shimadzu Class VP HPLC system (Japan) with a Thermo 
C18 column (10 mm×4.6 mm; 2.4 μm) combined with a UV 
detector was used for the drug content analysis. Analytical 
methods were developed according to the National Phar-
macopoeia II. IN was detected at a wavelength of 278 nm. 
The mobile phase comprised a mixture of methanol and 
0.02 mol L−1 Na2HPO4 solution (pH 6.45) at a ratio of 4:96 
(v/v). The flow rate was set at 0.5 mL min−1, the column 
temperature was 40°C, and the injection volume was 20 µL. 
High performance liquid chromatography-tandem mass 
spectrometry (HPLC-MS/MS) 
The HPLC-MS/MS system consisted of a 3200 Q TRAP® 
mass spectrometer (Applied Biosystems Inc., USA) 
equipped with an electrospray ionization (ESI) source sys-
tem and an Agilent 1200 HPLC system (Agilent Technolo-
gies, USA). Chromatographic separation of the analytes was 
performed on a Thermo C18 column (10 mm×4.6 mm; 2.4 
μm) equipped with a Thermo guard column. The mobile 
phase was a mixture of 0.2% formic acid in water and 
methanol (40:60; v/v), which was used at a flow rate of 0.4 
mL min−1. The column temperature was kept at 25°C 
throughout the elution process; the sample injection volume 
was 10 μL. The ESI source was operated in the positive 
mode and the final optimized conditions were as follows: 
nebulizer gas (Gas 1) 60 psi, auxiliary gas (Gas 2) 40 psi, 
spray voltage 5.5 kV, and turbo ion spray temperature 
400°C; cone voltage, 31 V for IN and 41 V for I.S.; and 
collision energy, 17 eV for IN and 43 eV for I.S. The quan-
tification analysis was performed under the multiple reac-
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tion monitoring (MRM) mode using the following transi-
tions: IN m/z 138.2–121.2 and gatifloxacin (I.S.) m/z 
376.2–261.0. All data were processed using the MassChrom 
software (version 1.4, Sciex, USA). 
Determination of the IN EE and LC 
The EE and LC were measured by extracting the IN from 
the microspheres. IN was extracted from the microspheres 
with water containing 25% DCM using ultrasonication for 2 
min. The measurements were repeated in triplicates. The 
extracted drug was analyzed using HPLC. The drug EE and 
LC were calculated from the following equations:  
Loading capacity (%)=(weight of drug in micro-
spheres/weight of microspheres)×100% 
Encapsulation efficiency (%)=(actual drug encapsulat-
ed/theoretical drug encapsulated)×100%. 
In vitro drug release 
The in vitro release test was carried out at pH 7.4 in PBS 
solution at 37±0.5°C. Twenty milligrams of PLA-IN-MS 
was suspended in the dialysis tubes with 3 mL of release 
medium. They were then transferred to an Erlenmeyer flask 
containing 200 mL of medium, incubated in a water bath 
(SHA-B (A), Jintankexi apparatus Co. Ltd., Jiangsu), and 
shaken at 100 strokes min−1 for 8 d. At pre-determined time 
intervals, 0.5 mL aliquots of the solutions were withdrawn 
and filtered through 0.45 μm filters. The sample volumes 
were replaced with equal volumes of the fresh medium. The 
IN released from the PLA-IN-MS was quantified using 
HPLC. Three tests were taken for each sample and the mean 
values were used as the final results. 
In vivo release 
SD rats were divided into two groups. After anesthesia us-
ing pentobarbital sodium (60 mg kg−1), the experimental 
group was administered 0.2 mL of the PLA-IN-MS suspen-
sion via an intratracheal intubation operation. The control 
group was administered with the same volume of a suspen-
sion of the PLA-IN-MIX. The rats were sacrificed at prede-
termined time intervals, and their tracheae and lung tissues 
were carefully separated to extract IN according to the BAL 
method previously reported. A specific amount of PBS was 
injected into the tracheae and lung tissues, and then with-
drawn immediately. The whole process was repeated four 
times. Methanol (360 μL) and 10 μL of the internal standard 
solution (0.96 μg mL−1 gatifloxacin) were put into the lav-
age fluid (130 μL), vortex-mixed for 2 min, and centrifuged 
at 13,000×g for 5 min. The supernatant was then collected 
and analyzed using high performance liquid chromatog-
raphy-tandem mass spectrometry. 
Statistical analysis 
Each experiment was conducted in triplicate; the statistical 
analysis was performed using the SPSS software (version 
17.0, SPSS Inc., USA). 
CONCLUSION 
In this study, PLA-IN-MS were prepared using the 
spray-drying technique, which was rapid and easy to con-
trol. Instead of a drug solution, the micronized IN powder 
(with an average particle size of approximately 160 nm) 
was directly dispersed into the oil phase and then this sus-
pension was spray-dried. Water was not introduced into the 
preparation process; therefore, this method overcomes the 
problems associated with the migration of water and drug 
during the emulsion and drying processes. Microspheres 
prepared using this technique were spherical, with a smooth 
and distorted morphology. A high EE (87.3%) was obtained 
using this method. In the in vivo release test, a relatively 
stable IN concentration was maintained for up to four weeks 
in rat lungs. This system has the potential to reduce the fre-
quency of administration and improve the therapeutic effi-
cacy of the intratracheal treatment of TB; therefore, we 
hope that these results will be helpful for the clinical treat-
ment of pulmonary tuberculosis. 
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